"Early" and "stable" are two essential qualifications for effective anticoagulant therapy in coronary disease, according to Dr. Paul A. Owren of Oslo.
Early institution of therapy permits anticoagulants to take effect before irreparable damage has been done to the myocardium, and while the threat of secondary thrombosis is greatest.
Maintaining as stable a therapeutic level of hypocoagulability as laboratory controls permit, reduces the risk of bleeding episodes to something "quite negligible."
Owren, head of the Department of Medicine at University Hospital, Oslo, and developer of the Owren thrombotest discussed his theories and conclusions with The Journal while he was in this country to address the American College of Chest Physicians, meeting in joint session with the AMA in Atlantic City in June.
Owren observed that at University Hospital, anticoagulant therapy has incurred a morbidity of one incident per 150 treatment years. A survey of 10 Norwegian hospitals showed a similar